GlassScriptPhysician profile
Oksana Barilyak
NPI 1588855498
$8,313.09
in general payments reported to CMS, 2019-2025
37 companies · $882 in 2025
The $882 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $1,109 · 2021: $418 · 2022: $1,285 · 2023: $1,858 · 2024: $1,436 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,175.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,577.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,079.77 | 2019-2025 | |
| Abbvie INC. | $661.98 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Amgen INC. | $655.24 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Glaxosmithkline, LLC. | $608.36 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Chugai Pharmaceutical Co., LTD. | $525.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $497.92 | 2019-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $334.06 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Lilly USA, LLC | $315.24 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $242.57 | 2019-2024 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.86 | 2019-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $159.37 | 2021-2023 | |
| Horizon Therapeutics Plc | $150.92 | 2019-2023 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.16 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $114.30 | 2023-2024 | Veozah, Myrbetriq |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oksana Barilyak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.